Welcome to our dedicated page for Acadia Healthcar SEC filings (Ticker: ACHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acadia Healthcare Company, Inc. SEC filings document the company's behavioral healthcare operations, public-company governance and capital structure. Its disclosures describe subsidiaries that own, operate or manage acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers, residential treatment centers and outpatient behavioral healthcare facilities in the U.S. and Puerto Rico.
Acadia's filings include Form 8-K reports on operating and financial results, Regulation FD materials, executive and director changes, separation and compensation arrangements, and shareholder voting outcomes. Proxy materials cover board elections, executive compensation, incentive compensation plans and annual-meeting proposals, while registered-security disclosures identify ACHC common stock on the NASDAQ Global Select Market.
Acadia Healthcare Company, Inc. director and Chief Executive Officer Debra K. Osteen filed a Form 3 reporting her beneficial ownership in the company’s common stock. She reported ownership of 3,765 shares of common stock, held directly, as of the event date of January 20, 2026. The filing does not list any derivative securities such as options or warrants.
Acadia Healthcare Company, Inc. announced a leadership transition in which Christopher H. Hunter departed as Chief Executive Officer and resigned from the Board, effective January 20, 2026. The Board appointed Debra K. Osteen as Chief Executive Officer, principal executive officer and a Class I director, with her Board term running until the 2027 annual meeting, and she will not receive additional pay for Board service.
Under a new employment agreement effective on the transition date, Ms. Osteen will receive a $1,061,000 annual base salary and be eligible for an annual cash bonus targeted at 125% of base salary. She also received a non-qualified stock option to purchase 1,125,000 shares of Acadia common stock at the January 20, 2026 closing price, with vesting tied to future stock price VWAP hurdles of $25.00, $35.00, and $45.00 and continued service conditions. The agreement includes severance protections for certain terminations and customary confidentiality, non-compete, non-solicitation and non-disparagement covenants.
Acadia Healthcare Company, Inc. is participating in the 44th Annual J.P. Morgan Healthcare Conference and is reaffirming its previously issued 2025 financial guidance that was provided in a November 5, 2025 earnings release and updated in a December 2, 2025 press release. Company representatives will discuss information contained in a slide presentation furnished as an exhibit.
The presentation will be webcast live through Acadia’s investor relations website starting at 5:15 p.m. Pacific / 7:15 p.m. Central on January 13, 2026, with a replay available online for thirty days. The company also reiterates that its forward-looking statements involve risks and uncertainties, highlighting factors such as integration of acquisitions, changes in Medicaid financing following the One Big Beautiful Bill Act, reimbursement trends, liability exposure, debt service needs, cybersecurity risks, and broader economic and industry conditions affecting its behavioral healthcare facilities in the U.S. and Puerto Rico.
Acadia Healthcare (ACHC) agreed to settle a previously disclosed securities case for $179 million, with no admission or finding of liability and subject to preliminary and final approval by the District Court. The Company plans to fund the payment from approximately $30 million in anticipated insurance proceeds, plus cash on hand and existing credit lines.
Acadia will record the aggregate settlement amount, less associated tax benefits, as an expense for the quarter ending December 31, 2025. Because the settlement funds will be excluded from adjusted EBITDA, the Company stated this has no impact on previously announced financial guidance. As of September 30, 2025, cash and cash equivalents were $118.7 million, availability under the $1.0 billion revolving credit facility was $786.7 million, and the Consolidated Total Net Leverage Ratio was 3.4x.
Acadia Healthcare (ACHC) reported Q3 2025 results with revenue of $851.6 million, up from $815.6 million a year ago. Net income attributable to the company was $36.2 million versus $68.1 million last year, and diluted EPS was $0.40 versus $0.74.
Year to date, operating cash flow reached $218.2 million. The company invested $478.6 million in capital expenditures and ended the quarter with cash of $118.7 million. Q3 “transaction, legal and other costs” were $42.9 million, including $38.7 million for government investigations. Payor mix remained weighted to Medicaid at 56.9% in the quarter.
Acadia refinanced its debt with a new Credit Facility comprising a $1.0 billion revolver and a $650.0 million term loan maturing in 2030, and issued $550.0 million of 7.375% Senior Notes due 2033, contributing to long‑term debt of $2.285 billion at quarter‑end. Under its $300.0 million share repurchase program authorized in 2025, the company bought back 1,706,625 shares for $50.4 million, leaving $250.0 million available.
Acadia Healthcare (ACHC) reported leadership changes and furnished quarterly results. The company announced that Chief Operating Officer Dr. Nasser Khan resigned effective November 3, 2025. Acadia entered a transition and separation agreement under which Dr. Khan will serve as executive advisor to the CEO through December 31, 2025 and receive a lump-sum payment of $515,000 no later than March 15, 2026. He remains eligible for a 2025 cash bonus based on actual performance as determined by the Board or its Compensation Committee.
Acadia has begun a search for a new COO, with Dr. Khan’s former responsibilities covered by other executive leaders in the interim. The company also furnished a press release with operating and financial results for the third quarter ended September 30, 2025 as an exhibit.
Acadia Healthcare (ACHC) reported an insider equity award for its Chief Financial Officer, Todd S. Young. On 10/27/2025, he acquired 48,445 shares of common stock at $0.00 per share. According to the filing, these shares will vest over three years in equal annual installments beginning 10/27/2026. Following this transaction, Young beneficially owned 48,445 shares, held directly.
Acadia Healthcare (ACHC): A Form 3 was filed for Chief Financial Officer Todd S. Young, reporting his initial beneficial ownership with the issuer. The filing states that no securities are beneficially owned.
The event date is 10/27/2025, and the Form 3 was signed by Brian Farley as attorney-in-fact on 10/28/2025 pursuant to an Exhibit 24 power of attorney.
Acadia Healthcare Company, Inc. disclosed an employment agreement for Todd Young dated October 7, 2025 that sets compensation and relocation terms for his role. The package includes a one-time $460,000 cash award payable by March 31, 2026 if he remains employed through that date, a one-time grant of time-based restricted stock units with a grant-date fair value of $1,200,000 that vest ratably over three years, and a minimum annual equity award for fiscal 2026 with grant-date fair value of at least $2,900,000. The agreement also provides eligibility for severance on certain terminations and reimbursement for reasonable relocation expenses to the greater Franklin, Tennessee area within 12 months of his start date.
The Vanguard Group reported owning 9,417,045 shares of Acadia Healthcare Company, Inc., representing 10.19% of the outstanding common stock as of 09/30/2025. Vanguard reports 0 shares of sole voting power, 598,737 shares of shared voting power, 8,718,595 shares of sole dispositive power, and 698,450 shares of shared dispositive power. The filing states these shares are held in the ordinary course of business and not for the purpose of changing or influencing control. The reporting address is 100 Vanguard Blvd., Malvern, PA, and the filing is signed by Ashley Grim, Head of Global Fund Administration, on 10/06/2025.